WASHINGTON--(BUSINESS WIRE)--An international medical specialty society today announced support for a proposed FDA label change that would affect the use of Optison, an ultrasound contrast agent marketed by GE Healthcare for use in improving the accuracy and reliability of radiation-free imaging procedures known as "contrast-enhanced ultrasound" (CEUS).
